<DOC>
	<DOCNO>NCT00076050</DOCNO>
	<brief_summary>The purpose study determine soy-derived phytoestrogens ( naturally occur compound similar estrogen ) prevent bone loss menopausal symptom woman recently go menopause . Study hypothesis : Tablets high-dose , purified soy phytoestrogens spare normally occur spinal bone loss improve biological emotional change menopause .</brief_summary>
	<brief_title>Using Soy Estrogens Prevent Bone Loss Other Menopausal Symptoms</brief_title>
	<detailed_description>The risk bone loss osteoporosis increase significantly menopause . Although hormone therapy ( HT ) spare menopausal woman bone loss menopausal symptom , Women 's Health Initiative ( WHI ) finding indicate significant potential health risk associate HT . This prompted woman switch HT naturally occur compound similar estrogen , derive soy , hope estrogen plant source provide benefit spar adverse effect cause prescribed estrogen . However , long-term efficacy safety plant estrogens unknown . This study evaluate effectiveness treatment use purified soy isoflavones , dietary source phytoestrogens , prevent bone loss , menopausal symptom , change associate estrogen deficiency young menopausal woman . The `` Soy Phytoestrogens As Replacement Estrogen ( SPARE ) '' study provide foundation knowledge menopausal woman doctor begin make informed decision regard HT treatment option . Enrollment study occur 3 year , participant take part study total 2 year . Participants randomly assign one two group ; first group receive 200 mg dose soy isoflavones daily second group receive placebo daily . There 10 study visit : screening , study entry , randomization Month 1 , six follow-up visit Months 2 , 4 , 8 , 12 , 16 , 20 , final visit end active participation Month 24 . At study visit , participant blood drawn , provide urine sample , answer questionnaire , mammogram bone density test .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Phytoestrogens</mesh_term>
	<criteria>Inclusion Criteria Absence menstrual period 12 month 5 year , absence menstrual period 6 12 month follicle stimulate factor ( FSH ) great 40 IU/L Exclusion Criteria Treatment estrogens , progesterone , raloxifene , tamoxifen Treatment bisphosphonates , calcitonin , fluoride , systemic corticosteroid Use soy/herbal supplement , include DHEA , within 3 month prior study entry Use antibiotic month prior study entry Use prescription medication treat hot flash Chemical menopause , include postchemotherapy Hyperthyroidism Hypothyroidism Uncontrolled diabetes Malabsorption syndromes chronic disease Body mass index ( BMI ) less 20 great 32 Bone mineral density ( BMD ) Tscore 2.0 lumbar spine femoral neck</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>